The high efficacy of muscarinic M4 receptor in D1 medium spiny neurons reverses striatal hyperdopaminergia
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The opposing action of dopamine and acetylcholine has long been known to play an important role in basal ganglia physiology. However, the quantitative analysis of dopamine and acetylcholine signal interaction has been difficult to perform in the native context because the striatum comprises mainly two subtypes of medium‐sized spiny neurons (MSNs) on which these neuromodulators exert different actions. We used biosensor imaging in live brain slices of dorsomedial striatum to monitor changes in intracellular cAMP at the level of individual MSNs. We observed that the muscarinic agonist oxotremorine decreases cAMP selectively in the MSN subpopulation that also expresses D1 dopamine receptors, an action mediated by the M4 muscarinic receptor. This receptor has a high efficacy on cAMP signaling and can shut down the positive cAMP response induced by dopamine, at acetylcholine concentrations which are consistent with physiological levels. This supports our prediction based on theoretical modeling that acetylcholine could exert a tonic inhibition on striatal cAMP signaling, thus supporting the possibility that a pause in acetylcholine release is required for phasic dopamine to transduce a cAMP signal in D1 MSNs. In vivo experiments with acetylcholinesterase inhibitors donepezil and tacrine, as well as with the positive allosteric modulators of M4 receptor VU0152100 and VU0010010 show that this effect is sufficient to reverse the increased locomotor activity of DAT‐knockout mice. This suggests that M4 receptors could be a novel therapeutic target to treat hyperactivity disorders. HIGHLIGHTSMuscarinic receptor activation decreases cAMP only in D1‐type striatal neurons.The M4 muscarinic receptor is the likely mediator of this effect.Extremely low levels of acetylcholine are sufficient to trigger this effect.Cholinergic neurons can thus control dopamine action in the striatum.M4 pharmacology revert hyperlocomotion in a genetic mouse model of hyperactivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A critical time window for dopamine actions on the structural plasticity of dendritic spines
Yagishita, S., Hayashi-Takagi, A., Ellis-Davies, G. C. R., Urakubo, H., Ishii, S., & Kasai, H. (2014) · Science · doi:10.1126/science.1255514 · Cited by 614
Coincident but Distinct Messages of Midbrain Dopamine and Striatal Tonically Active Neurons
Morris, G., Arkadir, D., Nevet, A., Vaadia, E., & Bergman, H. (2004) · Neuron · doi:10.1016/j.neuron.2004.06.012 · Cited by 574
Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders
Conn, P. J., Jones, C. K., & Lindsley, C. W. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.12.002 · Cited by 286
Meaningful silences: how dopamine listens to the ACh pause
Cragg, S. J. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.01.003 · Cited by 245
Cited by
Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias
van der Westhuizen, E. T., Choy, K. H. C., Valant, C., McKenzie-Nickson, S., Bradley, S. J., Tobin, A. B., Sexton, P. M., & Christopoulos, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.606656 · Cited by 63
“Dopamine transporter knockout mice have a reduction in dopamine reuptake from the synapse, resulting in an accumulation of synaptic dopamine levels and a characteristic hyperactivity phenotype (Gainetdinov et al., 1999; Carpenter et al., 2012; Nair et al., 2019).”
BackgroundInfluentialTargeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease
Dwomoh, L., Tejeda, G. S., & Tobin, A. B. (2022) · Neuronal Signaling · doi:10.1042/ns20210004 · Cited by 60
Association of Both Inhibitory and Stimulatory Gα Subunits Implies Adenylyl Cyclase 5 Deactivation
van Keulen, S. C., Narzi, D., & Rothlisberger, U. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00662 · Cited by 11
Metadata
- Authors
- Nair, A. G., Castro, L. R. V., El Khoury, M., Gorgievski, V., Giros, B., Tzavara, E. T., Hellgren-Kotaleski, J., & Vincent, P.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 146
- Pages
- 74-83
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2900782570
- Cited by
- 51
- References
- 4
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The high efficacy of muscarinic M4 receptor in D1 medium spiny neurons reverses striatal hyperdopaminergia. https://app.cochat.ai/papers/10.1016/j.neuropharm.2018.11.029
- The paper
- Nair, A. G., Castro, L. R. V., El Khoury, M., Gorgievski, V., Giros, B., Tzavara, E. T., Hellgren-Kotaleski, J., & Vincent, P. (2019). The high efficacy of muscarinic M4 receptor in D1 medium spiny neurons reverses striatal hyperdopaminergia. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2018.11.029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.